Participants with gametocytes at day 8, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.4 to 0.5 mg/kg probably leads to lower participants with gametocytes at day 8, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants infectious at day 8 · adults and children with malaria being treated with non‐artemisinin treatment
It is very uncertain whether single dose primaquine at 0.75 mg/kg changes participants infectious at day 5 compared with no primaquine, with non‐artemisinin partner, (very low certainty).
2 findings from 1 review
Participants with gametocytes at day 5, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.75 mg/kg showed no clear difference in participants with gametocytes at day 5, by microscopy compared with no primaquine, with non‐artemisinin partner, (low certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.75 mg/kg probably leads to lower participants with gametocytes at day 8, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg showed no clear difference in participants with gametocytes at day 3 to 4 by PCR compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg leads to lower participants with gametocytes at day 8 by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
Participants with severe haemolysis · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg showed no clear difference in participants with severe haemolysis compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants infectious at day 8 · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg may leads to lower participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
2 findings from 1 review
Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with gametocytes at day 3‐4, by PCR compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg leads to lower participants with gametocytes at day 8, by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
All‐cause mortality at 6 to 12 months · HIV‐positive people with cryptococcal meningitis
Early ART may leads to higher all‐cause mortality at 6 to 12 months compared with delayed ART initiation (low certainty).
1 finding from 1 review
Cryptococcal meningitis relapse · HIV‐positive people with cryptococcal meningitis
Early ART showed no clear difference in cryptococcal meningitis relapse compared with delayed ART initiation (low certainty).
1 finding from 1 review
Cryptococcal IRIS · HIV‐positive people with cryptococcal meningitis
It is very uncertain whether early ART changes cryptococcal IRIS compared with delayed ART initiation (very low certainty).
1 finding from 1 review
HIV virological suppression at 6 months (viral load < 400 copies/mL) · HIV‐positive people with cryptococcal meningitis
It is very uncertain whether early ART changes HIV virological suppression at 6 months (viral load < 400 copies/mL) compared with delayed ART initiation (very low certainty).
1 finding from 1 review
Clinical malaria episodes during pregnancy · HIV‐uninfected pregnant women
Mefloquine showed no clear difference in clinical malaria episodes during pregnancy compared with sulfadoxine‐pyrimethamine (high certainty).
1 finding from 1 review
Maternal parasitaemia (at delivery) · HIV‐infected pregnant women
Mefloquine plus cotrimoxazole probably leads to lower maternal peripheral parasitaemia at delivery (PCR) compared with cotrimoxazole (moderate certainty).
1 finding from 1 review
Placental malaria · HIV‐infected pregnant women
Mefloquine plus cotrimoxazole probably leads to lower placental malaria (PCR) compared with cotrimoxazole (moderate certainty).
1 finding from 1 review
Maternal anaemia at delivery · HIV‐infected pregnant women
Mefloquine plus cotrimoxazole showed no clear difference in maternal anaemia at delivery compared with cotrimoxazole (moderate certainty).
1 finding from 1 review
Low birthweight · HIV‐infected pregnant women
Mefloquine plus cotrimoxazole showed no clear difference in low birth weight compared with cotrimoxazole (moderate certainty).
1 finding from 1 review
Spontaneous abortions and stillbirths · HIV‐infected pregnant women
It is very uncertain whether mefloquine plus cotrimoxazole changes spontaneous abortions and stillbirths compared with cotrimoxazole (very low certainty).
1 finding from 1 review